🎉 M&A multiples are live!
Check it out!

CStone Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for CStone Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

CStone Pharmaceuticals Overview

About CStone Pharmaceuticals

CStone Pharmaceuticals is engaged in the development and commercialization of tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.


Founded

2015

HQ

Hong Kong
Employees

230

Financials

LTM Revenue $58.7M

LTM EBITDA -$19.7M

EV

$422M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

CStone Pharmaceuticals Financials

CStone Pharmaceuticals has a last 12-month revenue of $58.7M and a last 12-month EBITDA of -$19.7M.

In the most recent fiscal year, CStone Pharmaceuticals achieved revenue of $59.7M and an EBITDA of -$38.2M.

CStone Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See CStone Pharmaceuticals valuation multiples based on analyst estimates

CStone Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $61.9M $59.7M XXX XXX XXX
Gross Profit $17.6M $35.8M XXX XXX XXX
Gross Margin 28% 60% XXX XXX XXX
EBITDA -$109M -$38.2M XXX XXX XXX
EBITDA Margin -177% -64% XXX XXX XXX
Net Profit -$247M -$116M XXX XXX XXX
Net Margin -399% -195% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

CStone Pharmaceuticals Stock Performance

As of April 15, 2025, CStone Pharmaceuticals's stock price is HKD 3 (or $0).

CStone Pharmaceuticals has current market cap of HKD 3.6B (or $465M), and EV of HKD 3.3B (or $422M).

See CStone Pharmaceuticals trading valuation data

CStone Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$422M $465M XXX XXX XXX XXX $-0.02

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

CStone Pharmaceuticals Valuation Multiples

As of April 15, 2025, CStone Pharmaceuticals has market cap of $465M and EV of $422M.

CStone Pharmaceuticals's trades at 7.7x LTM EV/Revenue multiple, and -23.0x LTM EBITDA.

Analysts estimate CStone Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for CStone Pharmaceuticals and 10K+ public comps

CStone Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $422M XXX XXX XXX
EV/Revenue 7.1x XXX XXX XXX
EV/EBITDA -11.0x XXX XXX XXX
P/E -9.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get CStone Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

CStone Pharmaceuticals Valuation Multiples

CStone Pharmaceuticals's NTM/LTM revenue growth is 12%

CStone Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, CStone Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate CStone Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for CStone Pharmaceuticals and other 10K+ public comps

CStone Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -4% XXX XXX XXX XXX
EBITDA Margin -64% XXX XXX XXX XXX
EBITDA Growth -65% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -52% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue 43% XXX XXX XXX XXX
G&A Expenses to Revenue 11% XXX XXX XXX XXX
R&D Expenses to Revenue 114% XXX XXX XXX XXX
Opex to Revenue 191% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

CStone Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

CStone Pharmaceuticals M&A and Investment Activity

CStone Pharmaceuticals acquired  XXX companies to date.

Last acquisition by CStone Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . CStone Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by CStone Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About CStone Pharmaceuticals

When was CStone Pharmaceuticals founded? CStone Pharmaceuticals was founded in 2015.
Where is CStone Pharmaceuticals headquartered? CStone Pharmaceuticals is headquartered in Hong Kong.
How many employees does CStone Pharmaceuticals have? As of today, CStone Pharmaceuticals has 230 employees.
Who is the CEO of CStone Pharmaceuticals? CStone Pharmaceuticals's CEO is Dr. Jianxin Yang, M.D.,PhD.
Is CStone Pharmaceuticals publicy listed? Yes, CStone Pharmaceuticals is a public company listed on HKG.
What is the stock symbol of CStone Pharmaceuticals? CStone Pharmaceuticals trades under 02616 ticker.
When did CStone Pharmaceuticals go public? CStone Pharmaceuticals went public in 2019.
Who are competitors of CStone Pharmaceuticals? Similar companies to CStone Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of CStone Pharmaceuticals? CStone Pharmaceuticals's current market cap is $465M
What is the current revenue of CStone Pharmaceuticals? CStone Pharmaceuticals's last 12-month revenue is $58.7M.
What is the current EBITDA of CStone Pharmaceuticals? CStone Pharmaceuticals's last 12-month EBITDA is -$19.7M.
What is the current EV/Revenue multiple of CStone Pharmaceuticals? Current revenue multiple of CStone Pharmaceuticals is 7.7x.
What is the current EV/EBITDA multiple of CStone Pharmaceuticals? Current EBITDA multiple of CStone Pharmaceuticals is -23.0x.
What is the current revenue growth of CStone Pharmaceuticals? CStone Pharmaceuticals revenue growth between 2023 and 2024 was -4%.
Is CStone Pharmaceuticals profitable? Yes, CStone Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.